Trials / Completed
CompletedNCT02952092
A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia
A Phase 3, Multi-center, Randomized, 2-arm Parallel, Double-blind, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 303 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety and efficacy of ASP1517 compared to darbepoetin alfa in hemodialysis chronic kidney disease patients with anemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | roxadustat | Oral |
| DRUG | Darbepoetin alfa | Intravenous |
Timeline
- Start date
- 2016-11-30
- Primary completion
- 2018-03-13
- Completion
- 2018-03-15
- First posted
- 2016-11-02
- Last updated
- 2024-10-30
Locations
57 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02952092. Inclusion in this directory is not an endorsement.